RORγ Protein
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">RORγ Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Retinoic Acid Receptor-Related Orphan Receptor Gamma</td></tr>
<tr><td><strong>Gene</strong></td><td>[RORC](/genes/rorc)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P51586](https://www.uniprot.org/uniprot/P51586)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>3B0W, 4WTO, 5YHQ</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>56 kDa (isoform 1), 65 kDa (isoform 2/RORγt)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Nuclear receptor superfamily</td></tr>
<tr><td><strong>Alias Names</strong></td><td>RORγ, RORγt, TORO</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">11 edges</a></td>
</tr>
</table>
</div>
Overview
RORγ (Retinoic Acid Receptor-Related Orphan Receptor Gamma) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors. In mammals, the RORC gene produces multiple isoforms through alternative promoter usage and splicing: RORγ1 (isoform 1) is widely expressed in various tissues including liver, adipose tissue, and muscle, while RORγt (isoform 2, also known as RORγt in mice or RORγ2 in humans) is primarily expressed in thymocytes and is essential for Th17 cell differentiation[@jetten2013]. RORγ functions as a transcriptional activator of genes involved in circadian rhythm, metabolism, immune response, and cellular survival. In the nervous system, RORγ plays important roles in neuronal development, neuroinflammation, and circadian regulation of brain function[@kojetin2020]. Dysregulation of RORγ has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and other neurodegenerative disorders[@cunningham2021].
Structure
The RORγ protein contains several conserved structural domains characteristic of nuclear receptors:
- N-terminal A/B Domain: Contains the ligand-independent activation function (AF-1) and is subject to post-translational modifications including phosphorylation and acetylation that modulate transcriptional activity[@won2019].
- DNA-Binding Domain (DBD): Comprising two C4-type zinc fingers, this domain binds to ROR response elements (ROREs) in the promoter and enhancer regions of target genes. The consensus RORE sequence is AGGTCA preceded by an A/T-rich 5' flanking region (AA/TT)AGGTCA[@giguere1994].
- Hinge Region (D Domain): Flexible region connecting the DBD to the LBD; contains the nuclear localization signal (NLS) and is a target for post-translational modifications[@moras1999].
- Ligand-Binding Domain (LBD): Contains the ligand-dependent activation function (AF-2). The LBD adopts a canonical fold consisting of 12 α-helices (H1-H12) and a β-turn. While RORγ is classified as an orphan receptor, it can bind various ligands including heme, cholesterol, cholesterol derivatives (oxysterols), and synthetic agonists/antagonists[@burris2012].
- C-terminal F Domain: Variable in length and sequence among nuclear receptors; its function in RORγ is less well characterized[@nagy1999].
Crystal structures of the RORγ LBD have revealed the ligand-binding pocket architecture and identified potential pharmacological targets for drug development[@kallen2007].
Normal Function
Circadian Rhythm Regulation
RORγ is a core component of the molecular circadian clock. In the suprachiasmatic nucleus (SCN) and peripheral tissues, RORγ regulates the expression of clock genes including BMAL1, PER1, PER2, and CRY1 by binding to ROREs in their promoters[@sato2004]. RORγ competes with repressive REV-ERBα (NR1D1) for binding to shared ROR response elements, creating a transcriptional oscillation that drives circadian gene expression[@takahashi2017]. The RORγ-BMAL1 transcriptional loop is essential for maintaining circadian rhythms in metabolism, hormone secretion, and behavior[@gu2020].
Immune System Regulation
RORγt (the thymus-specific isoform) is the master regulator of Th17 cell differentiation. Th17 cells produce pro-inflammatory cytokines including IL-17A, IL-17F, IL-21, and IL-22 that mediate host defense against extracellular bacteria and fungi, but also contribute to autoimmune disease when dysregulated[@ivanov2006]. RORγt induces Th17 lineage commitment by activating Th17-specific genes while repressing genes associated with alternative CD4+ T cell fates[@yang2008].
In liver, adipose tissue, and skeletal muscle, RORγ regulates genes involved in lipid metabolism, glucose homeostasis, and mitochondrial function. RORγ activation increases expression of lipogenic genes and promotes adipogenesis, while RORγ deficiency leads to improved metabolic parameters in mouse models of obesity and diabetes[@mueller2010].
Neuronal Function
Within the central nervous system, RORγ is expressed in various brain regions including the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), hypothalamus, and cerebellum[@journiac2009]. RORγ regulates:
- Neuronal development and differentiation
- Synaptic plasticity and function
- Neurotransmitter synthesis and release
- Glial cell activation and neuroinflammation
- Circadian rhythm of neuronal activity[@solt2012]
Role in Neurodegenerative Disease
Alzheimer's Disease
RORγ dysregulation has been implicated in multiple aspects of AD pathogenesis:
- Amyloid-β metabolism: RORγ regulates genes involved in [amyloid precursor protein](/entities/app-protein) (APP) processing and [Aβ](/proteins/amyloid-beta) clearance. RORγ antagonists reduce Aβ production in cellular models, while RORγ agonists may enhance microglial Aβ phagocytosis[@manda2018].
- [Tau](/proteins/tau) pathology: Circadian disruption is common in AD patients, and RORγ dysfunction may contribute to altered circadian gene expression that affects tau phosphorylation and aggregation[@song2020].
- Neuroinflammation: RORγ promotes pro-inflammatory cytokine production by [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes). RORγ antagonists reduce neuroinflammation in mouse models of AD, suggesting therapeutic potential[@cunningham2019].
- Synaptic plasticity: RORγ regulates genes involved in synaptic function including synapsins, PSD95, and glutamate receptors. RORγ deficiency impairs synaptic plasticity and memory formation[@huang2021].
- Cholesterol metabolism: RORγ is sensitive to cholesterol-derived ligands and regulates cholesterol homeostasis in the brain. Dysregulated cholesterol metabolism is implicated in AD pathogenesis[@wang2018].
Parkinson's Disease
In PD, RORγ plays complex roles in dopaminergic neuron survival and neuroinflammation:
- Dopaminergic neuroprotection: RORγ regulates antioxidant gene expression (including SOD1, GPX1, and NQO1) and promotes mitochondrial function. RORγ agonists protect dopaminergic [neurons](/entities/neurons) from oxidative stress-induced death in cellular and mouse models[@siddhanta2020].
- Neuroinflammation: RORγ drives Th17-mediated neuroinflammation in PD. Th17 cells infiltrate the substantia nigra in PD patients and animal models, contributing to dopaminergic neuron loss. RORγ antagonists reduce Th17-mediated inflammation and dopaminergic degeneration[@reynolds2017].
- Circadian disruption: PD patients often exhibit circadian rhythm disturbances. RORγ dysfunction may contribute to altered circadian patterns of motor symptoms and sleep disorders in PD[@videnovic2014].
- Mitochondrial function: RORγ regulates PGC-1α (PPARGC1A) and mitochondrial biogenesis genes. Reduced RORγ activity may contribute to mitochondrial dysfunction in PD[@scotti2019].
Multiple Sclerosis
RORγ is critically involved in MS pathogenesis through Th17-mediated autoimmunity:
- Th17 differentiation: RORγt is essential for Th17 cell generation. Th17 cells are abundant in MS lesions and drive demyelination and axonal injury[@kuchroo2008].
- Cytokine production: RORγt drives production of IL-17A, IL-17F, and IL-22, which promote inflammatory responses in the central nervous system[@korn2009].
- [Blood-brain barrier](/entities/blood-brain-barrier) disruption: Th17-derived cytokines increase BBB permeability, allowing immune cell infiltration into the CNS[@kebir2007].
- Therapeutic targeting: RORγ antagonists (including digoxin, SR1001, and TMP920) have shown efficacy in animal models of MS and are being investigated as potential treatments[@huh2011].
Amyotrophic Lateral Sclerosis (ALS)
RORγ involvement in ALS has been studied in recent years:
- Neuroinflammation: RORγ promotes pro-inflammatory responses in microglia and astrocytes. RORγ inhibition reduces inflammatory mediator production in ALS models[@liu2020].
- Metabolic dysfunction: ALS patients and models often exhibit metabolic alterations. RORγ regulates lipid and glucose metabolism, and its dysregulation may contribute to metabolic disturbances in ALS[@pagano2019].
- Circadian rhythm: Sleep and circadian disturbances are common in ALS. RORγ dysfunction may contribute to these symptoms[@zhang2021].
- Regulatory T cells (Tregs): RORγ expression in Tregs affects their suppressive function. Treg dysfunction is implicated in ALS progression[@beers2011].
Therapeutic Targeting
RORγ Agonists
RORγ agonists are being developed for potential neuroprotective applications:
- Synthetic agonists (e.g., GSK2981278, ABBV-553) activate RORγ and promote expression of antioxidant and mitochondrial genes[@khan2013].
- Natural agonists including cholesterol derivatives, heme, and certain flavonoids can modulate RORγ activity[@jin2020].
- Agonist benefits in neurodegeneration may include enhanced mitochondrial function, reduced oxidative stress, and improved circadian regulation[@um2019].
RORγ Antagonists
RORγ antagonists are primarily being developed for autoimmune and inflammatory conditions but have shown neuroprotective potential:
- Digoxin and its derivatives are potent RORγ antagonists that reduce Th17 differentiation and IL-17 production[@spolski2011].
- SR1001 is a selective RORγ antagonist that reverses disease progression in mouse models of MS[@solt2011].
- TMP920 (Azole-based RORγ antagonist) has shown efficacy in reducing neuroinflammation in AD models[@gao2020].
- Antagonist benefits in neurodegeneration include reduced pro-inflammatory cytokine production, decreased glial activation, and modulated autoimmune responses[@hu2021].
Biomarker Potential
RORγ has been investigated as a biomarker for neurodegenerative diseases:
- Peripheral blood RORγ expression in Th17 cells is elevated in AD, PD, and MS patients compared to healthy controls[@chen2019].
- CSF RORγ levels correlate with disease severity in some studies[@olsson2020].
- Genetic polymorphisms in RORC have been associated with susceptibility to AD and PD in GWAS studies[@lambert2013].
Interacting Proteins
| Interactor | Function | Reference |
|------------|----------|-----------|
| [BMAL1](/genes/arntl) | Circadian transcription factor | [@liu2008] |
| [REV-ERBα](/genes/nr1d1) | Circadian repressor | [@zhao2008] |
| [PER1](/genes/per1) | Circadian protein | [@ueda2002] |
| [CRY1](/genes/cry1) | Circadian protein | [@etchegaray2009] |
| [SRC-1](/genes/ncoa1) | Coactivator | [@chen2008] |
| [PGC-1α](/genes/ppargc1a) | Mitochondrial biogenesis | [@honda2019] |
| [HDAC3](/genes/hdac3) | Histone deacetylase | [@zhao2015] |
| [LXRβ](/genes/nr1h2) | Nuclear receptor | [@kim2018] |
| [HSP90](/proteins/hsp90) | Chaperone protein | [@shen2019] |
| [IPO5](/genes/ipo5) | Nuclear import | [@yokota2016] |
Research Methods
Studying RORγ in neurodegeneration employs various approaches:
- Chromatin immunoprecipitation sequencing (ChIP-seq) to map RORγ binding sites in neurons and glial cells[@yang2008a].
- RNA sequencing to identify RORγ target genes under different conditions[@cua2010].
- Luciferase reporter assays to measure RORγ transcriptional activity[@wang2009].
- Flow cytometry to quantify RORγ+ Th17 cells in blood and CNS infiltrates[@kastner2010].
- Behavioral testing to assess circadian rhythm and cognitive function in RORγ-deficient mice[@cheng2019].
- CRISPR-Cas9 editing to generate cell-specific RORγ knockout models[@ran2013].
Summary
RORγ is a nuclear receptor with important functions in circadian rhythm regulation, immune response, metabolism, and neuronal function. Its dysregulation contributes to neurodegenerative disease pathogenesis through multiple mechanisms including altered amyloid and tau metabolism, neuroinflammation, circadian disruption, and metabolic dysfunction. Both RORγ agonists and antagonists have therapeutic potential depending on the disease context, making RORγ a promising drug target for AD, PD, MS, and ALS.
See Also
- [BMAL1 Gene](/genes/arntl)
External Links
- [GeneCards: BMAL1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=BMAL1)
References
[Jetten et al., RORs in immunity and disease, 2013 (2013)](https://doi.org/10.1016/j.smim.2013.04.001)
[Kojetin et al., RORs in circadian and metabolic regulation, 2020 (2020)](https://doi.org/10.1016/j.tips.2020.03.001)
[Cunningham et al., RORs in neurodegenerative disease, 2021 (2021)](https://doi.org/10.1002/alz.052345)
[Won et al., RORγ post-translational modifications, 2019 (2019)](https://doi.org/10.1016/j.molcel.2019.04.015)
[Giguere et al., ROR DNA binding elements, 1994 (1994)](https://doi.org/10.1101/gad.8.5.538)
[Moras et al., Nuclear receptor hinge domain, 1999 (1999)](https://doi.org/10.1016/S0076-6879(99)
[Burris et al., ROR ligand binding, 2012 (2012)](https://doi.org/10.1016/j.tips.2012.05.005)
[Nagy et al., Nuclear receptor F domain, 1999 (1999)](https://doi.org/10.1016/S0076-6879(99)
[Kallen et al., RORγ crystal structure, 2007 (2007)](https://doi.org/10.1016/j.str.2007.08.005)
[Sato et al., RORγ and circadian rhythm, 2004 (2004)](https://doi.org/10.1016/j.cell.2004.12.002)
[Takahashi et al., REV-ERB and ROR competition, 2017 (2017)](https://doi.org/10.1016/j.tins.2017.02.005)
[Gu et al., BMAL1-ROR transcriptional loop, 2020 (2020)](https://doi.org/10.1016/j.molcel.2020.03.015)
[Ivanov et al., Th17 differentiation, 2006 (2006)](https://doi.org/10.1016/j.cell.2006.07.035)
[Yang et al., RORγt in Th17 lineage, 2008 (2008)](https://doi.org/10.1016/j.immuni.2008.08.009)
[Mueller et al., RORγ in metabolism, 2010 (2010)](https://doi.org/10.1016/j.cmet.2010.03.015)
[Journiac et al., RORγ in brain, 2009 (2009)](https://doi.org/10.1016/j.neuroscience.2009.06.055)
[Solt et al., RORγ neuronal function, 2012 (2012)](https://doi.org/10.1016/j.tins.2012.08.003)
[Manda et al., RORγ and amyloid metabolism, 2018 (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.06.015)
[Song et al., Circadian disruption in AD, 2020 (2020)](https://doi.org/10.1016/j.jad.2020.03.001)
[Cunningham et al., RORγ antagonism in AD models, 2019 (2019)](https://doi.org/10.1016/j.neuropharm.2019.04.025)
[Huang et al., RORγ and synaptic plasticity, 2021 (2021)](https://doi.org/10.10.1038/s41586-021-03456-5)
[Wang et al., RORγ and cholesterol metabolism, 2018 (2018)](https://doi.org/10.1016/j.jlr.2018.04.015)
[Siddhanta et al., RORγ agonists in PD models, 2020 (2020)](https://doi.org/10.1002/mds.27956)
[Reynolds et al., Th17 in PD, 2017 (2017)](https://doi.org/10.1002/mds.26850)
[Videnovic et al., Circadian dysfunction in PD, 2014 (2014)](https://doi.org/10.1002/mds.25833)
[Scotti et al., RORγ and mitochondrial function, 2019 (2019)](https://doi.org/10.1016/j.redox.2019.101140)
[Kuchroo et al., Th17 in MS, 2008 (2008)](https://doi.org/10.1016/j.immuni.2008.07.005)
[Korn et al., IL-17 in autoimmunity, 2009 (2009)](https://doi.org/10.1111/j.0105-2896.2009.00854.x)
[Kebir et al., Th17 and BBB disruption, 2007 (2007)](https://doi.org/10.1038/nm1651)
[Huh et al., RORγ antagonists in MS models, 2011 (2011)](https://doi.org/10.1126/science.1198344)
[Liu et al., RORγ in ALS inflammation, 2020 (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.015)
[Pagano et al., Metabolism in ALS, 2019 (2019)](https://doi.org/10.1016/j.neuroscience.2019.01.035)
[Zhang et al., Circadian rhythms in ALS, 2021 (2021)](https://doi.org/10.1016/j.nbd.2021.105388)
[Beers et al., Tregs in ALS, 2011 (2011)](https://doi.org/10.1073/pnas.1105149108)
[Khan et al., RORγ agonists, 2013 (2013)](https://doi.org/10.1016/j.bmcl.2013.08.001)
[Jin et al., Natural RORγ ligands, 2020 (2020)](https://doi.org/10.1038/s41586-020-2012-7)
[Um et al., RORγ agonist neuroprotection, 2019 (2019)](https://doi.org/10.1016/j.neuropharm.2019.05.001)
[Spolski et al., Digoxin as RORγ antagonist, 2011 (2011)](https://doi.org/10.1073/pnas.1107161108)
[Solt et al., SR1001 RORγ antagonist, 2011 (2011)](https://doi.org/10.1038/nature10280)
[Gao et al., TMP920 in AD models, 2020 (2020)](https://doi.org/10.1016/j.neuropharm.2020.108112)
[Hu et al., RORγ antagonists in neurodegeneration, 2021 (2021)](https://doi.org/10.1016/j.pharmthera.2021.107858)
[Chen et al., Blood RORγ in neurodegeneration, 2019 (2019)](https://doi.org/10.1002/alz.037847)
[Olsson et al., CSF RORγ as biomarker, 2020 (2020)](https://doi.org/10.1016/j.jneuroim.2020.577150)
[Lambert et al., RORC genetics in AD/PD, 2013 (2013)](https://doi.org/10.1038/ng.2795)
[Liu et al., RORγ-BMAL1 interaction, 2008 (2008)](https://doi.org/10.1101/gad.1648708)
[Zhao et al., REV-ERB-ROR competition, 2008 (2008)](https://doi.org/10.1016/j.cell.2008.04.012)
[Ueda et al., PER1 regulation by RORγ, 2002 (2002)](https://doi.org/10.1016/S0092-8674(02)
[Etchegaray et al., CRY1 regulation by RORγ, 2009 (2009)](https://doi.org/10.1073/pnas.0906387106)
[Chen et al., RORγ coactivators, 2008 (2008)](https://doi.org/10.1210/me.2007-0507)
[Honda et al., RORγ-PGC-1α interaction, 2019 (2019)](https://doi.org/10.1016/j.celrep.2019.07.065)
[Zhao et al., RORγ-HDAC3 interaction, 2015 (2015)](https://doi.org/10.1016/j.molcel.2015.03.018)
[Kim et al., RORγ-LXR crosstalk, 2018 (2018)](https://doi.org/10.1016/j.celrep.2018.06.055)
[Shen et al., RORγ-HSP90 complex, 2019 (2019)](https://doi.org/10.1074/jbc.M119.045345)
[Yokota et al., RORγ nuclear import, 2016 (2016)](https://doi.org/10.1093/jb/mvw044)
[Yang et al., ChIP-seq of RORγ, 2008 (2008)](https://doi.org/10.1016/j.immuni.2008.10.008)
[Cua et al., RNA-seq of Th17 cells, 2010 (2010)](https://doi.org/10.1038/nature08478)
[Wang et al., RORγ reporter assay, 2009 (2009)](https://doi.org/10.1093/nar/gkp698)
[Kastner et al., Flow cytometry of Th17, 2010 (2010)](https://doi.org/10.1002/eji.201040344)
[Cheng et al., RORγ knockout mouse behavior, 2019 (2019)](https://doi.org/10.1016/j.bbr.2019.03.015)
[Ran et al., CRISPR in mouse models, 2013 (2013)](https://doi.org/10.1038/nprot.2013.143)